Atrial fibrillation: an epidemic in the elderly

References

• Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am. J. Cardiol.104(11), 1534–1539 (2009).
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Wang TJ, Leip EP et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation110(9), 1042–1046 (2004).
   PubMed Web of Science ®Google Scholar
• Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA285(18), 2370–2375 (2001).
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke22(8), 983–988 (1991).
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation98(10), 946–952 (1998).
   PubMed Web of Science ®Google Scholar
• Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am. J. Med.113(5), 359–364 (2002).
   PubMed Web of Science ®Google Scholar
• Kwok CS, Loke YK, Hale R, Potter JF, Myint PK. Atrial fibrillation and incidence of dementia: a systematic review and meta-analysis. Neurology76(10), 914–922 (2011).
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Levy, D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA271(11), 840–844 (1994).
   PubMed Web of Science ®Google Scholar
• Tsang TS, Gersh BJ, Appleton CP et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J. Am. Coll. Cardiol.40(9), 1636–1644 (2002).
   PubMed Web of Science ®Google Scholar
• Djousse L, Levy D, Benjamin EJ et al. Long-term alcohol consumption and the risk of atrial fibrillation in the Framingham Study. Am. J. Cardiol.93(6), 710–713 (2004).
   PubMed Web of Science ®Google Scholar
• Haissaguerre M, Jais P, Shah DC et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N. Engl. J. Med.339(10), 659–666 (1998).
   PubMed Web of Science ®Google Scholar
• Aldhoon B, Melenovsky V, Peichl P, Kautzner J. New insights into mechanisms of atrial fibrillation. Physiol Res.59(1), 1–12 (2010).
   Google Scholar
• Everett TH, Olgin JE. Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm4(Suppl. 3), S24–S27 (2007).
   PubMed Web of Science ®Google Scholar
• Xu J, Cui G, Esmailian F et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation109(3), 363–368 (2004).
   PubMed Web of Science ®Google Scholar
• Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J. Am. Coll. Cardiol.51(8), 802–809 (2008).
   PubMed Web of Science ®Google Scholar
• Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med.347(23), 1825–1833 (2002).
   PubMed Web of Science ®Google Scholar
• Corley SD, Epstein AE, DiMarco JP et al. Relationships between sinus rhythm, treatment and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. Circulation109(12), 1509–1513 (2004).
   PubMed Web of Science ®Google Scholar
• Van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N. Engl. J. Med.347(23), 1834–1840 (2002).
   PubMed Web of Science ®Google Scholar
• Van Gelder IC, Groenveld HF, Crijns HJ et al. Lenient versus strict rate control in patients with atrial fibrillation. N. Engl. J. Med.362(15), 1363–1373 (2010).
   PubMed Web of Science ®Google Scholar
• Fuster V, Ryden LE, Cannom DS et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J. Am. Coll. Cardiol.57(11), e101–e198 (2001).
   Google Scholar
• The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N. Engl. J. Med.321(6), 406–412 (1989).
   PubMed Web of Science ®Google Scholar
• McNamara RL, Tamariz LJ, Segal JB, Bass EB. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion and echocardiography. Ann. Intern. Med.139(12), 1018–1033 (2003).
   PubMed Web of Science ®Google Scholar
• Siddoway LA. Amiodarone: guidelines for use and monitoring. Am. Fam. Phys.68(11), 2189–2196 (2003).
   PubMed Web of Science ®Google Scholar
• Singh BN, Connolly SJ, Crijns HJ et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N. Engl. J. Med.357(10), 987–999 (2007).
   PubMed Web of Science ®Google Scholar
• Kober L, Torp-Pedersen C, McMurray JJ et al. Increased mortality after dronedarone therapy for severe heart failure. N. Engl. J. Med.358(25), 2678–2687 (2008).
   PubMed Web of Science ®Google Scholar
• Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J. Cardiovasc. Electrophysiol.21(6), 597–605 (2010).
   PubMed Web of Science ®Google Scholar
• Nault I, Sanders P, Shah A et al. Pulmonary vein isolation for atrial fibrillation. In: Catheter Ablation of Cardiac Arrhythmias. Wood MA (Ed.). Saunders, PA, USA, 234–264 (2011).
   Google Scholar
• Cappato R, Calkins H, Chen SA et al. Updated worldwide survey on the methods, efficacy and safety of catheter ablation for human atrial fibrillation. Circ. Arrhythm. Electrophysiol.3(1), 32–38 (2011).
   Google Scholar
• Tan HW, Wang XH, Shi HF et al. Efficacy, safety and outcome of catheter ablation for atrial fibrillation in octogenarians. Int. J. Cardiol.145(1), 147–148 (2009).
   Google Scholar
• Ouyang F, Tilz R, Chun J et al. Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up. Circulation122(23), 2368–2377 (2010).
   PubMed Web of Science ®Google Scholar
• Weerasooriya R, Khairy P, Litalien J et al. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up? J. Am. Coll. Cardiol.57(2), 160–166 (2011).
   PubMed Web of Science ®Google Scholar
• Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur. Heart J.31(19), 2369–2429 (2010).
   PubMed Web of Science ®Google Scholar
• Tzou WS, Marchlinski FE, Zado ES et al. Long-term outcome after successful catheter ablation of atrial fibrillation. Circ. Arrhythm Electrophysiol.3(3), 237–242 (2010).
   PubMed Web of Science ®Google Scholar
• Singer DE, Albers GW, Dalen JE et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest133(Suppl. 6), S546–S592 (2008).
   Google Scholar
• Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke39(6), 1901–1910 (2008).
   PubMed Web of Science ®Google Scholar
• Gage BF, Waterman AD, Shannon, W, Boechler, M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA285(22), 2864–2870 (2001).
   PubMed Web of Science ®Google Scholar
• Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation114(7), e257–e354 (2006).
   PubMed Web of Science ®Google Scholar
• Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest137(2), 263–272 (2010).
   PubMed Web of Science ®Google Scholar
• Olesen JB, Lip GY, Hansen ML et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ342(d124), 1–9 (2011).
   Google Scholar
• van Walraven C, Hart RG, Singer DE et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA288(19), 2441–2448 (2002).
   PubMed Web of Science ®Google Scholar
• Singer DE, Chang Y, Fang MC et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann. Intern. Med.151(5), 297–305 (2009).
   PubMed Web of Science ®Google Scholar
• Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation115(21), 2689–2696 (2007).
   PubMed Web of Science ®Google Scholar
• Gage BF, Fihn SD, White RH. Management and dosing of warfarin therapy. Am. J. Med.109(6), 481–488 (2000).
   PubMed Web of Science ®Google Scholar
• Brass LM, Krumholz HM, Scinto JM, Radford M. Warfarin use among patients with atrial fibrillation. Stroke28(12), 2382–2389 (1997).
   PubMed Web of Science ®Google Scholar
• Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch. Intern. Med.159(7), 677–685 (1999).
   PubMed Web of Science ®Google Scholar
• Mant J, Hobbs FD, Fletcher K et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet370(9586), 493–503 (2007).
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med.146(12), 857–867 (2007).
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med.361(12), 1139–5111 (2009).
   PubMed Web of Science ®Google Scholar
• Wann LS, Curtis AB, Ellenbogen KA et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J. Am. Coll. Cardiol.57(11), 1330–1337 (2011).
   PubMed Web of Science ®Google Scholar
• Kinch JW, Davidoff R. Prevention of embolic events after cardioversion of atrial fibrillation. Current and evolving strategies. Arch. Intern. Med.155(13), 1353–1360 (1995).
   Google Scholar
• Stoddard MF, Dawkins PR, Prince CR, Longaker RA. Transesophageal echocardiographic guidance of cardioversion in patients with atrial fibrillation. Am. Heart J.129(6), 1204–1215 (1995).
   Google Scholar
• Klein AL, Grimm RA, Jasper SE et al. Efficacy of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation at 6 months: a randomized controlled trial. Am. Heart J.151(2), 380–389 (2006).
   PubMed Web of Science ®Google Scholar
• Klein AL, Grimm RA, Murray RD et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N. Engl. J. Med.344(19), 1411–1420 (2001).
   PubMed Web of Science ®Google Scholar
• Silverman DI, Manning WJ. Role of echocardiography in patients undergoing elective cardioversion of atrial fibrillation. Circulation98(5), 479–486 (1998).
   Google Scholar
• Nagarakanti R, Ezekowitz MD, Oldgren J et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation123(2), 131–136 (2011).
   PubMed Web of Science ®Google Scholar
• Patel M. Stroke prevention using the oral direct factor Xa inhibitor rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation (ROCKET AF). Circulation122(21), 2217 (2010).
   Google Scholar
• Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N. Engl. J. Med.364(9), 806–817 (2011).
   PubMed Web of Science ®Google Scholar
• Fuster V, Rydén LE, Cannom DS et al. ACC/AHA/ESC 2006 Guidelines for the Management of patients with atrial fibrillation. J. Am. Coll. Cardiol.48(4), 854–906 (2006).
   PubMed Web of Science ®Google Scholar